A Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value

Area of Science:

• Oncology
• Immunology
• Biomarker Research

Background:

• Pleural mesothelioma (PM) presents diagnostic and therapeutic challenges with variable patient prognoses.
• Identifying reliable prognostic factors is crucial for effective clinical management.
• The pan-Immune-Inflammation-Value (PIV) is a novel, easily calculated peripheral blood biomarker.

Purpose of the Study:

• To investigate the prognostic value of the pan-Immune-Inflammation-Value (PIV) in patients with pleural mesothelioma.
• To assess the correlation between PIV and other blood-based inflammatory markers (PLR, NLR, SII) with patient outcomes.
• To evaluate PIV's utility in predicting overall survival (OS) and disease-free survival (DFS).

Main Methods:

• Retrospective observational study of 95 patients with pleural mesothelioma (stages I-IV).
• Calculation of PIV using the formula: (neutrophil count × monocyte count × platelet count)/lymphocyte count.
• Analysis of demographic, clinicopathological factors, and blood parameters (PIV, PLR, NLR, SII) against survival data.

Main Results:

• High PIV values were significantly associated with poorer overall survival (OS) (median 14.7 months vs. 29.8 months, p < 0.001).
• Low PIV, NLR, and SII correlated with earlier disease stages and surgical eligibility.
• PIV, NLR, and SII predicted disease-free survival (DFS) in the surgical cohort and treatment response.

Conclusions:

• The pan-Immune-Inflammation-Value (PIV) is an independent and significant prognostic factor for OS and DFS in pleural mesothelioma.
• PIV demonstrates superior prognostic value compared to other tested blood-based markers in this cohort.
• PIV is a promising, cost-effective, and practical tool for clinical management of pleural mesothelioma.